Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Shots:

• The company reports the availability of Amgevita, referencing Humira to treat 11 chronic inflammatory conditions in Canada
• Amgevita is available as a prefilled syringe and a prefilled pen (SureClick autoinjector) with a broad range of pack sizes to support dosing for each indication and available in a citrate-free formulation. Amgevita is reimbursed on the public drug for all indications of Humira in British Columbia, Alberta, Ontario, Quebec, New Brunswick and Newfoundland
• The approval was based on the clinical study that supports bio-similarity with the Humira and showed no clinical differences from the reference product

Click here to­ read full press release/ article | Ref: Amgen | Image: Amgen